Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2152137 | 0.90 | ALDH1A1 (0.53) | ALDH1A1TDP1MAPK1L3MBTL1KMT2A | |
| SCHEMBL4102278 | 0.88 | ALDH1A1 (0.50) | ALDH1A1TDP1MAPK1L3MBTL1KMT2A | |
| SCHEMBL22812898 | 0.88 | ALDH1A1 (0.52) | ALDH1A1TDP1MAPK1L3MBTL1KMT2A | |
| SCHEMBL20663521 | 0.86 | ALDH1A1 (0.49) | ALDH1A1TDP1MAPK1L3MBTL1KMT2A | |
| SCHEMBL29414961 | 0.85 | CETP (0.51) | CYP4F2CYP4A11ALDH1A1TDP1MAPK1 | |
| SCHEMBL6393090 | 0.84 | ALDH1A1 (0.53) | ALDH1A1TDP1MAPK1L3MBTL1KMT2A | |
| SCHEMBL3726946 | 0.84 | CYP4F2 (0.49) | CYP4F2CYP4A11ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL6714511 | 0.84 | ALDH1A1 (0.46) | ALDH1A1TDP1MAPK1L3MBTL1KMT2A | |
| Ammonia Solution, Strong SCHEMBL27836903 | 0.84 | CETP (0.50) | CYP4F2CYP4A11ALDH1A1TDP1MAPK1 | |
| Ammonia Solution, Strong SCHEMBL27817446 | 0.84 | CETP (0.50) | CYP4F2CYP4A11ALDH1A1TDP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024358-B1 | SUBSTITUTED SPIROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2029575-B1 | SUBSTITUTED SPIROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2404890-A1 | Hydroxyl compounds and compositions for cholesterol management and related uses | Esperion Therapeutics Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| US-7893079-B2 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100056498-A1 | SUBSTITUTED MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-03-04 | — | — | US | disclosed |
| US-7629338-B2 | Substituted monocyclic CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7625901-B2 | Substituted monocyclic CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| EP-2029575-A1 | SUBSTITUTED SPIROCYCLIC CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-2024358-A1 | SUBSTITUTED SPIROCYCLIC CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20080318927-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2008-12-25 | — | — | US | disclosed |
| WO-2008020902-A1 | SUBSTITUTED SPIROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007133491-A1 | SUBSTITUTED SPIROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056498-A1 | SUBSTITUTED MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | QRFPR, CALCRL, EDNRB | CYP4F2 1703/4885CYP4A11 1526/4885ALDH1A1 1847/4885 |
| US-20080318927-A1 | Substituted monocyclic CGRP receptor antagonists | EDNRB, CALCRL, QRFPR | CYP4F2 1560/4885CYP4A11 1548/4885ALDH1A1 1839/4885 |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | QRFPR, CALCRL, EDNRB | CYP4F2 1703/4885CYP4A11 1526/4885ALDH1A1 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.